Cargando…
An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature includ...
Autores principales: | Alroughani, Raed, Inshasi, Jihad Said, Deleu, Dirk, Al-Hashel, Jasem, Shakra, Mustafa, Elalamy, Osama Robin, Shatila, Ahmed Osman, Al-Asmi, Abdullah, Al Sharoqi, Isa, Canibano, Beatriz Garcia, Boshra, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534637/ https://www.ncbi.nlm.nih.gov/pubmed/30875021 http://dx.doi.org/10.1007/s40120-019-0129-0 |
Ejemplares similares
-
Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
por: Inshasi, Jihad, et al.
Publicado: (2021) -
Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
por: Alroughani, Raed, et al.
Publicado: (2020) -
The use of alemtuzumab in patients with relapsing-remitting multiple
sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020) -
Impact of the first Gulf war on multiple sclerosis risk in Kuwait: a quasi-experimental study
por: Akhtar, Saeed, et al.
Publicado: (2023) -
Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East
por: Alroughani, Raed, et al.
Publicado: (2022)